News
The randomized control period of the MINT trial has completed, and these newest data describe outcomes among patients who ...
On the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, the adjusted mean difference between inebilizumab and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results